Procarbazine
- Generic Name
- Procarbazine
- Brand Names
- Matulane
- Drug Type
- Small Molecule
- Chemical Formula
- C12H19N3O
- CAS Number
- 671-16-9
- Unique Ingredient Identifier
- 35S93Y190K
- Background
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
- Indication
For use with other anticancer drugs for the treatment of stage III and stage IV Hodgkin's disease.
- Associated Conditions
- Non-Hodgkin's Lymphoma (NHL), Oligodendroglioma, Primary Central Nervous System Lymphoma, Stage III Hodgkin's Disease, Stage IV Hodgkin's Disease
- Associated Therapies
- -
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 6
- Registration Number
- NCT01390584
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 331
- Registration Number
- NCT01251107
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy
Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma
- Conditions
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2009-10-05
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 56
- Registration Number
- NCT00989352
- Locations
- 🇩🇪
University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology, Freiburg, Germany
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 305
- Registration Number
- NCT00887146
- Locations
- 🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00577993
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 26
- Registration Number
- NCT00335140
- Locations
- 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
🇺🇸Bronson Methodist Hospital, Kalamazoo, Michigan, United States
HD12 for Advanced Stages
- Conditions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- University of Cologne
- Registration Number
- NCT00265031
HD11 for Intermediate Stages
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2011-08-04
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1395
- Registration Number
- NCT00264953
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.